Publication|Articles|November 17, 2026

Evidence-Based Oncology

  • November 2026
  • Volume 32
  • Issue Spec 12
  • Pages: SP678-SP680

Emerging Threats to Cell and Gene Therapy Access

Listen
0:00 / 0:00

Key Takeaways

  • Fully insured MCO policies generally cover pre-2024 CGTs with trial-aligned criteria, but self-insured employers can bypass Essential Health Benefits and state mandates, creating heterogeneous access.
  • Stop-loss dynamics incentivize gene therapy exclusions, lasering, and carve-outs, forcing manufacturers to tailor value narratives to employers’ utilization forecasts, downstream costs, and productivity impacts.
SHOW MORE

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."

We are in the 10th year since cell and gene therapies (CGTs) have been commercially available in the United States. In that time, the number of therapies has expanded to more than 30 marketed products and includes 4 products—onasemnogene abeparvovec-xioi (Zolgensma; Novartis), axicabtagene ciloleucel (Yescarta; Kite/Gilead), lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb), and ciltacabtagene autoleucel (Carvykti; Janssen)—that have exceeded or are expected to exceed annual global sales of $1 billion.1-4 The US managed care industry anticipated this growth and has responded with novel management tools for cell and gene therapy.

Insurance coverage may be less of an issue than benefit inclusion in employer-sponsored health plans.

On the surface, cell and gene therapy coverage looks favorable. Each of the top 5 managed care organizations (MCOs) maintains a published commercial medical policy providing coverage for CGTs approved before 2024 in their fully insured commercial health plans. Coverage differs by payer; in over 80% of these cases, these therapies are covered with similar or less restrictive eligibility criteria to the pivotal clinical trials, just like most other specialty drugs.5

However, many large employer-sponsored health plans are self-insured and not required to conform to these coverage policies. Private employer self-insured health plans are also not required to include all Essential Health Benefits, or to conform to most state regulations on which benefits must be covered.6,7

As gene therapy costs increase, self-funded employers face greater exposure to stop-loss lasering, exclusions, increasing premiums, nonrenewal, prompting gene therapy carve-outs and supplemental stop-loss coverage. There is a growing trend of employers ”lasering out” gene therapies from medical benefits. In these cases, the employer has indicated that they do not offer it to their employees, regardless of medical necessity. Although the employee can appeal to their employer for reimbursement of the therapy, this exposes the employer to discrimination claims if they choose to reimburse some therapies outside the benefit but not others.

Employers and employer groups are becoming important stakeholders in CGT access, alongside the MCOs that administer their health benefits. They are the ultimate access gatekeepers for many working-age adults and their dependents. Manufacturers should tailor their value communication to reflect employers’ distinct priorities, including anticipated utilization among specific patient populations, financial responsibility for follow-up care, and the broader impact on patient and caregiver quality of life and productivity, including absenteeism and wage replacement. As a result, the value arguments that resonate with employers may differ substantially from those developed for traditional payer stakeholders.

Limiting access to Qualified Treatment Centers may be contributing to missed or delayed referrals.

CGTs differ from most other specialty drugs in that they are limited to specific Qualified Treatment Centers (QTCs). Some MCOs, including Aetna, use more limited networks of QTCs for certain members.8

Research estimates that only 20% to 30% of clinically eligible patients within a treatment center catchment area are prescribed a chimeric antigen receptor (CAR) T-cell therapy for certain indications.9 Community physicians may have concerns about continuity of care or lost revenue when they refer out. They may question whether the patient has the social and logistical support to drive long distances to a QTC. These barriers create delays in referral that can result in patients “aging out” or progressing past the point at which they are eligible for CGTs. A few weeks of delay in referral can be critical.

Following the FDA’s June 2025 elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements for the 6 then-approved B-cell maturation antigen– and CD19-directed autologous CAR T-cell therapies,10 outpatient use has continued to expand. A 2026 analysis citing Prime Therapeutics medical claims reported that the hospital outpatient department’s share of CAR T-cell therapy administration increased from 16% in 2022 to 35% in 2025. Removal of REMS reduced federal site-certification and monitoring burdens, while greater provider experience, improved toxicity management, and the potential to avoid inpatient capacity constraints and costs are supporting the shift.10-12

However, growth in outpatient administration should not be interpreted as broad diffusion across community sites. Wider community adoption still depends on trained clinical staff, Foundation for the Accreditation of Cellular Therapy (FACT) accreditation, or payer acceptance of alternative standards, manufacturer and payer site authorization, dependable reimbursement and net cost recovery, apheresis and logistics capabilities, and formal hospital escalation pathways for adverse-event management. Sites with outpatient transplant or bispecific step-up experience may be better positioned to expand first, suggesting expansion is likely to remain concentrated among experienced, infrastructure-ready centers.

Real-world data can help identify potential gaps and delays across the CGT patient journey. Longitudinal data sources, including medical and prescription claims, electronic health records, diagnostic information, and relevant contextual data, can be used to characterize patterns of diagnosis, treatment, health care utilization, and referral across patient populations and geographic regions. These insights can help stakeholders identify where potentially eligible patients may not be progressing to specialist evaluation or authorized treatment centers and inform targeted interventions to strengthen referral pathways and improve access to treatment. Commercial teams can see where the missing referrals are originating and devise tactical plans to address them.

Proposed reforms to rare disease regulatory pathways may put further pressure on access.

Proposed US reforms to rare-disease regulatory pathways remain relevant. In February 2026, the FDA issued draft guidance describing a “Plausible Mechanism Framework” for certain individualized therapies targeting severely debilitating or life-threatening genetic conditions with known biological causes, particularly when sufficiently powered randomized trials are not feasible because patient populations are extremely small.13

The proposed framework would permit flexible use of mechanistic, natural-history, nonclinical, clinical, and biomarker evidence to support approval, accompanied by continued postapproval collection of safety and effectiveness data.13 Although the guidance remains in draft form and its implementation is not yet final, the proposed approach could, on the positive side, accelerate the development and availability of certain individualized therapies.

At the same time, if approval occurs with a less mature evidence package, some of the resulting uncertainty may shift downstream to payers, employers, and treatment centers. This could contribute to more cautious initial coverage decisions, including narrower eligibility criteria, case-by-case review, or requests for additional real-world evidence. Manufacturers should therefore develop integrated evidence plans that anticipate both regulatory and access requirements. Early approval does not guarantee early or consistent access.

Increasing outpatient administration of CGTs makes 340B reform a major uncertainty for CGTs.

As providers gain experience with CGT administration, CAR T-cell therapy is shifting toward outpatient delivery. A 2026 analysis citing Prime Therapeutics medical claims reported more than a 2-fold increase in outpatient administration from 2022 to 2025.12 Separate Medicare fee-for-service claims research found that 45% of facility outpatient CAR T-cell claims in 2024 were associated with 340B discount pricing.14 Outpatient treatment can reduce inpatient capacity pressure and may improve provider economics at eligible sites, but it can also increase manufacturers’ 340B exposure and make treatment center participation more sensitive to outpatient reimbursement and net cost recovery.

The 340B policy outlook now extends beyond potential changes to Medicare hospital outpatient payment. In July 2026, the Health Resources and Services Administration announced a revised 340B Rebate Model Pilot Program that would allow qualifying manufacturers to provide the 340B ceiling price through a postpurchase rebate rather than an upfront discount for a limited set of drugs selected for Medicare negotiation in initial price applicability years 2026 and 2027. Manufacturer plans were due August 24, 2026, and approved plans would take effect January 1, 2027.15 CAR T-cell therapies are not currently identified as included products; however, the model creates a precedent that is strategically relevant to high-cost outpatient therapies. If a rebate approach were later extended to cell and gene therapies, 340B-covered providers could face greater upfront acquisition costs, claims-submission requirements, rebate reconciliation, and timing risk before receiving the 340B value.

For therapies costing hundreds of thousands of dollars, that working-capital exposure could weaken outpatient economics, particularly for lower-volume or less-capitalized sites, and could slow onboarding or concentrate treatment at larger systems. At the same time, transaction-level validation may reduce manufacturers’ risk of duplicate discounts. Manufacturers should monitor the pilot, quantify provider cash-flow sensitivity, and consider reimbursement, payment-terms, and operational support that preserves provider willingness to offer treatment as administration shifts to outpatient.

Author Information

Mannat Sharma, MBIOT, is director of US Pricing and Market Access, Clarivate; Moira Ringo, PhD, MBA, was employed by Clarivate at the time of the writing of this paper; and Benjamin Jagt, MPH, is associate consultant, US Pricing and Market Access, Clarivate.

References

  1. Gilead Sciences announces fourth quarter and full year 2025 financial results. News release. Gilead. February 10, 2026. Accessed October 13, 2026. https://www.gilead.com/news/news-details/2026/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results
  2. Novartis Annual Report 2025. Novartis. February 3, 2026. Accessed October 13, 2026. https://www.novartis.com/news/media-library/novartis-annual-report-2025
  3. Johnson & Johnson reports Q4 and full-year 2025 results. News release. Johnson & Johnson. January 21, 2026. Accessed October 13, 2026. https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q4-and-Full-Year-2025-results/default.aspx
  4. 2025 Annual Report. Bristol Myers Squibb. March 25, 2026. Accessed October 13, 2026. https://annual-report.bms.com/
  5. Analysis of United, Aetna, Cigna, Anthem, and Centene medical policies. Accessed on or before August 2026.
  6. Pestaina K, Wallace R, Long M. The regulation of private health insurance. KFF. October 8, 2025. Accessed October 13, 2026. https://www.kff.org/health-policy-101-the-regulation-of-private-health-insurance/?entry=table-of-contents-what-is-private-health-insurance
  7. Frequently Asked Questions on Essential Health Benefits Bulletin. CMS. December 16, 2011. Accessed October 13, 2026. https://www.cms.gov/CCIIO/Resources/Files/Downloads/ehb-faq-508.pdf
  8. Aetna Institutes Gene Based, Cellular and Other Innovative Therapy (GCIT) Designated Centers. Aetna. https://www.aetna.com/content/dam/aetna/pdfs/health-care-professionals/GCIT-designated-providers.pdf
  9. Expanding access to CAR T-cell therapy. Accessed October 22, 2026. The University of Kansas Cancer Center. https://www.kucancercenter.org/news-room/news/2025/07/expanding-access-to-car-t-cell-therapy
  10. FDA eliminates Risk Evaluation and Mitigation Strategies (REMS) for autologous chimeric antigen receptor (CAR) T-cell immunotherapies. FDA. June 26, 2025. Accessed October 13, 2026. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor
  11. Kapexhiu G, Fein AJ. REMS removed: why CAR-T’s expansion into community oncology could benefit the big three wholesalers. Drug Channels. August 18, 2026. Accessed October 13, 2026. https://www.drugchannels.net/2026/08/rems-removed-why-car-ts-expansion-into.html
  12. Decker S, Eckwright D, Wilson A, Parikh P. Real-world assessment of cost and utilization trends of chimeric antigen receptor T-cell therapy and bispecific T-cell engager antibody therapy among different sites of care. Presented at: AMCP 2026, April 13-16, 2026; Nashville, TN. Abstract 342. Accessed September 30, 2026. https://www.primetherapeutics.com/documents/d/primetherapeutics/evt_ext_670100-i_realworldassessmentofcostutilizationtrends_r3-2_web
  13. Guidance document: Considerations for the use of the plausible mechanism framework to develop individualized therapies that target specific genetic conditions with known biological cause. FDA. February 25, 2026. Accessed October 13, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific
  14. REMS removal likely to spur CAR-T growth—and 340B financial risk. BluePath Solutions. Accessed October 13, 2026. https://www.bluepathsolutions.com/featured/rems-removal-likely-to-spur-car-t-growth-and-340b-financial-risk/
  15. HRSA announces revised 340B rebate model pilot program to strengthen care in rural and medically underserved communities. News release. Health Resources and Services Administration. July 31, 2026. Accessed October 13, 2026. https://www.hrsa.gov/about/news/press-releases/revised-340b-program-2026


Related to this article